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Abstract: The kidneys play key roles in the maintenance of homeostasis, including fluid balance,
blood filtration, erythropoiesis and hormone production. Disease-driven perturbation of renal
function therefore has profound pathological effects, and chronic kidney disease is a leading cause of
morbidity and mortality worldwide. Successive annual increases in global chronic kidney disease
patient numbers in part reflect upward trends for predisposing factors, including diabetes, obesity,
hypertension, cardiovascular disease and population age. Each kidney typically possesses more
than one million functional units called nephrons, and each nephron is divided into several discrete
domains with distinct cellular and functional characteristics. A number of recent analyses have
suggested that signaling between these nephron regions may be mediated by microRNAs. For this
to be the case, several conditions must be fulfilled: (i) microRNAs must be released by upstream
cells into the ultrafiltrate; (ii) these microRNAs must be packaged protectively to reach downstream
cells intact; (iii) these packaged microRNAs must be taken up by downstream recipient cells without
functional inhibition. This review will examine the evidence for each of these hypotheses and discuss
the possibility that this signaling process might mediate pathological effects.
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1. Introduction
The Kidneys
The kidneys are a pair of bean-shaped organs located within the retroperitoneal space, either side
of the spinal column. The left kidney is situated between vertebral levels T12 to L3, with the right
kidney resting slightly inferior, due to displacement by the liver [1]. In human adult males, each kidney
is approximately 11 cm in length, and weighs approximately 150 g.
Renal functions in the maintenance of homeostasis include the regulation of acid-base balance,
osmolality, blood pressure and extracellular fluid volume. In addition, the kidneys produce hormones,
including calcitriol, angiotensin, and aldosterone.
The functional unit of the kidney is the nephron (Figure 1). Each kidney possesses approximately
1.3 million nephrons and each nephron is composed of several regions: The Bowman’s capsule that is
intimately associated with the glomerulus in the renal corpuscle; the proximal convoluted tubule (PCT);
the loop of Henlé; the distal convoluted tubule (DCT) and the collecting duct.
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Figure 1. The nephron—the functional unit of the kidney. A different color is used to highlight each 
nephron domain. The direction of ultrafiltrate flow is shown with black arrows, bold arrows signify 
secretion of waste products (red) and solute reabsorption (green). PCT, proximal convoluted tubule; 
DCT, distal convoluted tubule. 
Blood filtration takes place in the Bowman’s capsule. The PCT, loop of Henlé, DCT and collecting 
duct are concerned with selective solute reabsorption and secretion of waste components between 
the ultrafiltrate and the circulation. The ultrafiltrate then leaves the collecting duct en route to the 
renal papilla and then the bladder, from which it is excreted as urine. This direction of flow from 
glomerulus through the nephron dictates the course taken by ultrafiltrate-borne microRNAs 
(miRNAs) and of any signaling mediated by these transcripts. 
Underlining the importance of the kidneys’ physiological roles during homeostasis, renal 
pathologies, such as chronic kidney disease, diabetic kidney disease, acute kidney injury, renal 
cancer, glomerulonephritis, and polycystic kidney disease, lead to widespread morbidity and 
mortality that place a significant burden on health services worldwide. 
A more complete understanding of the processes underlying communication within the kidney 
promises to provide novel targets for disease prevention and treatment strategies [2]. Here we will 
review the evidence for miRNA-mediated intra-nephron signaling and for pathological effects 
mediated by this mechanism. 
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2. microRNAs
2.1. Discovery and Evolutionary Conservation of microRNAs
microRNAs were first identified in 1993 [3,4] and are found in algae, viruses, plants, invertebrates,
and vertebrates [5–7]. miRNA-mediated silencing mechanisms show ancient evolutionary origins [8].
The sequences that give rise to miRNAs may be located in introns of protein coding genes, in exons
and introns of long noncoding RNAs and in intergenic regions [9]. miRNAs are single-stranded RNA
transcripts most often of ~22 nucleotides in length, with strong secondary structure motifs. Mature
miRNAs may be clustered into families based on their nucleotide sequences [5].
2.2. Biogenesis of miRNAs
As summarized in Figure 2 below, most miRNAs are transcribed by RNA polymerase II as
primary miRNAs (pri-miRNAs) that exceed 200 nucleotides in length. Pri-miRNAs are next cleaved
into 60–70 nucleotide hairpin precursor miRNAs (pre-miRNAs) by the Microprocessor multiprotein
complex, a dimer composed of RNAse III enzyme Drosha and double-stranded RNA binding protein
Pasha/DGCR8.
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Figure 2. Nuclear transcription and export of icroR As ( iRNAs), and their roles in translational
repression. RISC, RNA-induced silencing complex.
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Pre-miRNAs are exported from the nucleus to the cytoplasm by Exportin-5, where they are
processed by a second RNAse III enzyme, Dicer. Dicer cleavage results in the formation of mature
~22 nucleotide long miRNA/miRNA* duplexes with a guide strand and a passenger strand, denoted
here by an asterisk, which is degraded when the duplex divides. The guide strand associates with
several RNA binding proteins, including argonaute 2 (Ago2), to form the microribonuclear protein
(miRNP) complex known as the RNA-induced silencing complex (RISC) (Figure 2). The mature
miRNA may silence target gene expression via two mechanisms: Binding to a target messenger
RNA (mRNA) strand thereby preventing its translation and/or through promoting target mRNA
degradation. Biogenesis of miRNAs is reviewed in detail elsewhere [10].
By widespread regulation of target mRNA translation and subsequent protein expression,
miRNAs help modulate the physiological processes that maintain homeostasis. Dysregulated miRNA
expression has been reported in the pathophysiology of numerous diseases, including malignancies
and cardiovascular disease [11].
2.3. microRNAs in Kidney Health and Disease
Key roles for miRNAs have been reported in all types of renal cell, demonstrating their importance
in kidney development and the maintenance of homeostatic kidney physiology [12]. Aberrant miRNA
expression has been observed in renal diseases, including kidney cancer, acute kidney injury, end-stage
renal disease, diabetic nephropathy and polycystic kidney disease [13–20].
As described above, Dicer processes pre-miRNAs to mature miRNAs in canonical miRNA
biogenesis, but non-canonical miRNA synthesis pathways have also been described [21,22]. Germline
Dicer knockout in mice results in non-viability, reflecting the crucial importance of miRNAs in
development [23]. In the kidney, podocyte-specific Dicer knockout results in glomerular and proximal
tubular injury with accompanying proteinuria [24–26] with similar results for Drosha ablation [27].
By contrast, it has been reported that proximal tubular-specific Dicer knockouts result in normal
renal function and protection against renal ischemia-related injury, although in this model significant
residual miRNA expression was quantifiable [28]. Dicer’s miRNA-independent roles [29,30] might
also complicate interpretation of data from models employing Dicer deletion.
In order to propose miRNAs as communicators between segments of the nephron, renal cells
must demonstrate the capacity to release miRNAs, package them appropriately for protected transport
through the ultrafiltrate, and to take up functional miRNAs from the extracellular environment,
which are able to exert a phenotypic effect on the recipient cell.
Table 1 below presents data on selected miRNAs in kidney health and disease. We apologize
to those authors whose work we were unable to include, due to the volume of publications in
this area. Excellent and comprehensive recent reviews covering this area include Rong et al. [31],
and Gomez et al. [32].
Table 1. MiRNAs implicated in kidney disease pathologies. MCs, mesangial cells. DN,
diabetic nephropathy.
microRNA Up/Down-Regulationin Disease/Model Identified Target Disease/Model References
MiR-192
Up SIP-1 Mouse Model, MCs (human, rat, mouse) [33]
Down Zeb2 DN patient samples, ProximalTubule cells [34,35]
MiR-29c Up Sproutyhomolog-1/HIF1α Mouse Model, MCs (mouse) [36,37]
MiR-21
Up Smad7 Mouse Model, MCs (rat) [38]
Up PPARa Human Kidney Biopsy [39]
Up MMP-9, TIMP1 Mouse Model, MCs (rat) [40]
Down PTEN Mouse Model, Primary MCs (mouse) [41]
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Table 1. Cont.
microRNA Up/Down-Regulationin Disease/Model Identified Target Disease/Model References
MiR-215
Up CTNNBIP1 Mouse Model, Primary MCs (mouse) [37]
Down Zeb2 Mouse Model, Primary MCs and PTCs (rat) [35]
MiR-200b/c Up Zeb1/2 Mouse Model, MCs (mouse),Endothelial cells [42,43]
MiR-29b Down TGFBR Mouse Model [44]
MiR-216a Up PTENYbx1 Mouse Model, Primary MCs (mouse) [45]
MiR-25 Down NOX4 Human Biopsy, MCs [46]
MiR-29a Down COL4α1/2 Proximal Tubule cells [47]
3. Intra-Nephron microRNA Transport
3.1. Extracellular Vesicle Nomenclature
As discussed below, many reports describe the presence of extracellular vesicle-associated
and non-extracellular vesicle-associated miRNAs in body fluids. For the purposes of this review,
wherever possible we will use the definitions from the recent comprehensive review by van Niel and
colleagues [48]. Briefly, when extracellular vesicles (EVs) are formed by plasma membrane budding
they are referred to as microvesicles (MVs), and fall typically within the 50–500 nm size range, but may
be as large as 1 µm. A second population of EVs is generated within the lumen of multivesicular
endosomes. Fusion of these endosomes with the plasma membrane results in the release of this second
EV population, which are referred to as exosomes and typically range in size from 50–150 nm [48].
Nevertheless, the reader should be aware of significant inconsistencies in past use of the terms EV,
microvesicle and exosome, and the wide variety of methods that have been used in EV isolation.
Further details are not within the remit of this review and may be obtained from the cited sources.
Hypothesis 1. miRNAs are released into the upstream ultrafiltrate.
3.2. Cellular Release of microRNAs
To date, comparatively little data on intra-renal miRNA transport have been reported. However,
numerous cell types release EVs, including dendritic cells [49], lymphocytes [50,51], endothelial
cells [52,53], mast cells [54], epithelial cells [55] and tumor cells [56]. Consequently, EVs have been
found in a range of body fluids, including saliva [57], blood plasma [58], cerebrospinal fluid [59],
amniotic fluid [60], pleural fluid [61], and urine [62]. The work of Valadi and colleagues first described
the presence of RNAs, including miRNAs, in exosomes released by mast cells [63].
Proteomic profiling of human urinary exosomes has revealed the presence of proteins specifically
expressed in the following nephron segments: Glomerular podocytes, proximal tubule, thick ascending
limb of Henle, distal convoluted tubule, collecting duct, and transitional epithelia from the urinary
drainage system [60,62,64,65].
The above data support the hypothesis that renal cells release exosomes into the ultrafiltrate.
Hypothesis 2. Released miRNAs are sufficiently stable to reach downstream cells intact.
3.3. Extracellular microRNA Stability
As part of immune surveillance against viral infection, biological fluids, including urine, contain
highly active RNA-degrading ribonucleases [66–68]. Consistent with this, we found that synthetic
Caenorhabditis elegans miR-39 added to human urine was degraded very rapidly [69]. By contrast,
stability of cell-free endogenous miRNAs has been demonstrated in plasma, serum, urine and tissue
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culture medium, suggesting protection from endogenous ribonucleases [69–74]. miRNAs in the
extracellular space may be stabilized by association with EVs [69,75] (Figure 3), and a recent study has
comprehensively demonstrated the stability of EV-associated circulating miRNAs [76].
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However, extracellular miRNAs do not associate exclusively with EVs (Figure 3). Wang and
co-workers [77] exposed human cells to acute stress and analysed the culture medium. Subsequent
differential centrifugation revealed the presence of miRNAs in centrifugation pellets containing EVs
(referre t ereafter as EV-associated or EVA), and EV-free fractions ( on-EVA). Supporting these
findin , rroyo et al. [72] reported two distinct opulations of plasma-borne miRNAs:
EVA- i te ith vesicular ultracentrifugation fractions coll cted with painstaking
precision t t re, and non-EVA-miRNAs.
T i l also reported tha the majority of plasma miRNAs were non-EVA-miRNAs
associate it I co ponent Ago2 (Figure 2) [72]. Associati n of plasma non-EVA-miRNAs with
Ago1 [78] and go2 as also reported elsewhere [73,78]. Western blot analysis of both plasma and
conditioned cell culture media following ultrafiltration showed association of most non-EVA-miRNAs
with Ago2 [73], which is believed to confer stability and protection from degradation [69,72,79].
Non-coding RNA 2018, 4, 30 7 of 13
Our laboratory is investigating the use of miRNAs in urine and other body fluids as kidney
disease biomarkers [14,18–20,34,80–82]. On the basis of the above studies, we analyzed human urine
for presence on EVA and non-EVA-miRNAs [69]. Using established and optimized ultracentrifugation
protocols for isolation of intact EVs [83], we showed association of miR-16 and miR-192 with exosomal
and non-exosomal EV fractions [69]. We then used RNA-immunoprecipitation to show association of
these miRNAs with AGO2 [69].
High-density lipoproteins (HDLs) have also been implicated in the transport of miRNAs in the
extracellular circulatory environment [84]. This relationship was first proposed following the finding
that purified HDL fractions from human plasma contained miRNAs [84]. Transmission electron
microscopy allowed visualization of immunoprecipitated miRNA-HDL complexes that were clearly
distinguishable from EVs [84]. This association has the potential to protect miRNAs from ribonuclease
activity, and these authors proposed that miRNA-HDL transport represented an alternative form of
intercellular signaling [84] a theme that has attracted considerable further attention [85]. Low-density
lipoprotein (LDL) fractions from human plasma also contain miRNAs, but LDLs are less robust
miRNA carriers than HDLs [84,85]. Consequently, LDLs have received less attention in the context
of miRNA transport. A new pipeline for systematic analysis of lipoprotein-associated miRNAs has
been developed to expedite acquisition of this knowledge [86]. HDLs and LDLs are too large to pass
through the glomerular filtration barrier into the ultrafiltrate, and so are not predicted to play a part
in intraluminal miRNA transport within the nephron. However, it is conceivable that other, as yet
undiscovered, miRNA chaperones may be found in the ultrafiltrate.
Collectively, the above corroborate the hypothesis that miRNAs leaving nephron cells are
protected sufficiently from endogenous urinary ribonucleases.
Hypothesis 3. Downstream cells take up functional miRNAs from the ultrafiltrate.
3.4. Downstream Uptake of microRNAs
To date, much of the analysis of miRNA cellular uptake has focused on EVA-miRNAs. The process
of EV binding to target cells is likely directed by recipient cell surface receptors and EV membrane
protein composition: Following binding, internalization by endocytosis may be clathrin-mediated
or -independent, vesicular fate is dictated by their composition and target cell plasma membrane
structure. Once EVs have fused with the recipient cell, they elicit functional responses by receptor
activation at the recipient cell surface, and EV-miRNA and mRNA cargoes can activate responses
following internalization [48,63,87]. While the process of miRNA extracellular transport is now widely
accepted, the active/passive components of EV miRNA loading remain unresolved [88].
Exosomes were first implicated in the mediation of cell-to-cell communication via antigen
presentation [51]. Valadi and colleagues [63] subsequently showed the presence of exosome-associated
mRNAs and miRNAs from human and mast cell lines, and primary mouse mast cells. These authors
demonstrated de novo protein synthesis from transferred mRNA, suggesting that this represented a
novel mechanism of inter-cellular genetic exchange [63]. The concept of exosomes as novel mediators
of horizontal genetic transfer between cells soon expanded to include miRNAs synthesized in response
to viral infection, and mitochondrial DNA [89,90].
Numerous studies have described the regulation of target genes by EV-transported miRNAs.
Delivery of miR-126 in endothelial EVs derived from human aortic smooth muscle cells (HASMCs)
targeted regulator of G protein signaling 16 (RGS16) following transfer to human umbilical
vein endothelial cells (HUVECs), thereby inducing CXCL12 expression via CXCR4 [91]. Collino
and colleagues [92] showed that MVs delivered endogenous and synthetic miRNAs, and noted
downregulated expression of phosphatase and tensin homologue (PTEN), cyclin D1 and B cell
lymphoma 2 (Bcl-2), which they attributed to transferred miRNAs [92].
Zhang and co-workers [93] transfected fluorescently tagged synthetic miR-150 into THP-1
cells. MVs subsequently isolated from these cellswere then added to human dermal microvascular
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endothelial cells and miR-150 transfer was observed, which resulted in reduced protein levels of
oncoprotein c-Myb. Communication between endothelial and HASMCs has been reported to confer
an atheroprotective effect [94]. Transcription factor Krüppel-like factor 2 (KLF2) induces expression
of miR-143 and miR-145. KLF2-transduced HUVECs produced EVs enriched in these miRNAs,
and subsequent co-culture with untreated HASMCs resulted in significantly decreased HASMC
expression of 6 miRNA target genes, including ETS transcription factor family protein ELK1 and matrix
metalloproteinase 3 (MMP3) [94]. A further study has shown reduced adipogenesis and lipogenesis in
porcine adipocytes as a result of PPAR-γ repression, driven by EV-shuttled miR-130b [95].
Of direct relevance to the kidney, a recent study presents time-lapse video evidence showing EVs
moving into renal proximal tubule cells by EV uptake, and also reports EV uptake by renal distal tubule
cells and collecting duct cells [96]. These authors also present evidence for functional transfer of PTC EVs to
distal tubule and collecting duct cells, positing that this provided proof of a proximal-to-distal intra-nephron
transfer between upstream proximal tubular cells and downstream recipients [96]. Furthermore, recent
sequence analysis has identified 276 mature miRNAs in urinary exosomes from healthy subjects and
observed enrichment of miR-10, miR-30 and let-7 families [97]. Cultured cells from human renal proximal
tubular cell line HKC-8 were then seen to take up urinary exosomes, which was followed by translational
repression of potassium channel ROMK and kinases SG1 and WNK1 [97].
Taken together, these studies provide strong supportive evidence for the uptake and function of
EVA-miRNAs by renal and other cells. Comparatively little attention has so far been paid to transfer of
functional non-EVA-miRNAs. As discussed above, there is strong evidence for HDL-mediated miRNA
transport in the circulation, and non-EVA-miRNAs are readily detectable in urine. The potential for
alternate non-EVA-miRNA transport and signaling mechanisms in paracrine miRNA signaling within
the nephron is an important area for future study.
4. Conclusions
The experimental studies detailed above provide strong support for the hypothesis that
endogenous miRNAs function as intra-nephron communicators. Key roles for miRNAs in disease
processes in the kidney are emerging. A complete understanding of intra-nephron miRNA transport
and function might permit the use of relevant miRNAs as biomarkers. Such biomarkers are intended
to provide a non-invasive method of measuring response to treatment in a patient with kidney disease,
or a mechanism by which likely response to treatment could be predicted. MiRNAs are also entering
testing as direct targets of therapy, and as a potential therapy approach themselves. Understanding the
mechanisms by which miRNAs are protected, packaged and taken up by target cells in the nephron
may provide valuable insights for novel approaches to miRNA therapy.
5. Patents
T.B. and D.J.F. are inventors for patent WO/2017/129977 Chronic Kidney Disease Diagnostic.
Author Contributions: M.J.T. performed the corresponding literature search, wrote a draft version of the
manuscript and created the corresponding figures. T.B. revised and edited the manuscript. D.J.F. revised
the final version of the manuscript.
Funding: This work was funded by a Knowledge Economy Skills Scholarship award to M.J.T., and Kidney Research
UK project grant award RP44/2014. The Wales Kidney Research Unit is funded by Health and Care Research Wales.
Non-Coding RNA 2018, 4, x FOR PEER REVIEW  8 of 13 
 
expression of 6 miRNA target genes, including ETS transcription factor family protein ELK1 and 
matrix metalloproteinase 3 (MMP3) [94]. A further study has shown reduced adipogenesis and 
lipogenesis in porcine adipocytes as a result of PPAR-γ repression, driven by EV-shuttled miR-130b 
[95]. 
Of direct relevance to the kidney, a recent study presents time-lapse video evidence showing 
EVs moving into renal proximal tubule cells by EV uptake, and also reports EV uptake by renal distal 
tubule cells and collecting duct cells [96]. These authors also present evidence for functional transfer 
of PTC EVs to distal tubule and collecting duct cells, positing that this provided proof of a proximal-
to-distal intra-nephron transfer between upstream proximal tubular cells and downstream recipients 
[96]. Furthermore, recent sequence analysis has identified 276 mature miRNAs in urinary exosomes 
from healthy subjects and observed enrichment of miR-10, miR-30 and let-7 families [97]. Cultured 
cells from human renal proximal tubular cell line HKC-8 were then seen to take up urinary exosomes, 
which was followed by translational repression of potassium channel ROMK and kinases SG1 and 
WNK1 [97]. 
Taken together, these studies provide strong supportive evidence for the uptake and function of 
EVA-miRNAs by renal and other cells. Comparatively little attention has so far been paid to transfer 
of functional non-EVA-miRNAs. As discussed above, there is strong evidence for HDL-mediated 
miRNA transport in the circulation, and non-EVA-miRNAs are readily detectable in urine. The 
potential for alternate non-EVA-miRNA transport and signaling mechanisms in paracrine miRNA 
signaling within the nephron is an important area for future study. 
4. Conclusions 
The experimental studies detailed above provide strong support for the hypothesis that 
endogenous miRNAs function as intra-nephron communicators. Key roles for miRNAs in disease 
processes in the kidney are emerging. A complete understanding of intra-nephron miRNA transport 
and function might permit the use of relevant miRNAs as biomarkers. Such biomarkers are intended 
to provide a non-invasive method of measuring response to treatment in a patient with kidney 
disease, or a mechanism by which likely response to treatment could be predicted. MiRNAs are also 
entering testing as direct targets of therapy, and as a potential therapy approach themselves. 
Understanding the mechanisms by which miRNAs are protected, packaged and taken up by target 
cells in the nephron may provide valuable insights for novel approaches to miRNA therapy. 
5. Patents 
T.B. and D.J.F. are inventors for patent WO/2017/129977 Chronic Kidney Disease Diagnostic. 
Author Contributions: M.J.T. performed the corresponding literature search, wrote a draft version of the 
manuscript and created the corresponding figures. T.B. revised and edited the manuscript. D.J.F. revised the 
final version of the manuscript. 
Funding. This work was funded by a Knowledge Economy Skills Scholarship award to M.J.T., and Kidney 
Research UK project grant award RP44/2014. The Wales Kidney Research Unit is funded by Health and Care 
Research Wales. 
  
Conflicts of Interest: The authors declare no conflict of interest. 
References 
Non-coding RNA 2018, 4, 30 9 of 13
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Du, B.; Yu, M.; Zheng, J. Transport and interactions of nanoparticles in the kidneys. Nat. Rev. Mater. 2018, 3,
358–374. [CrossRef]
2. Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and
other diseases. Nat. Rev. Drug Discov. 2017, 16, 203–222. [CrossRef] [PubMed]
3. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. Elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell 1993, 75, 843–854. [CrossRef]
4. Wightman, B.; Ha, I.; Ruvkun, G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4
mediates temporal pattern formation in C. Elegans. Cell 1993, 75, 855–862. [CrossRef]
5. Griffiths-Jones, S.; Saini, H.K.; van Dongen, S.; Enright, A.J. Mirbase: Tools for microRNA genomics.
Nucleic Acids Res. 2008, 36, D154–D158. [CrossRef] [PubMed]
6. Lee, R.C.; Ambros, V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294, 862–864.
[CrossRef] [PubMed]
7. Moran, Y.; Agron, M.; Praher, D.; Technau, U. The evolutionary origin of plant and animal microRNAs.
Nat. Ecol. Evol. 2017, 1, 27. [CrossRef] [PubMed]
8. Mauri, M.; Kirchner, M.; Aharoni, R.; Ciolli Mattioli, C.; van den Bruck, D.; Gutkovitch, N.; Modepalli, V.;
Selbach, M.; Moran, Y.; Chekulaeva, M. Conservation of miRNA-mediated silencing mechanisms across
600 million years of animal evolution. Nucleic Acids Res. 2017, 45, 938–950. [CrossRef] [PubMed]
9. Rodriguez, A.; Griffiths-Jones, S.; Ashurst, J.L.; Bradley, A. Identification of mammalian microRNA host
genes and transcription units. Genome Res. 2004, 14, 1902–1910. [CrossRef] [PubMed]
10. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509–524. [CrossRef]
[PubMed]
11. Lekka, E.; Hall, J. Noncoding RNAs in disease. FEBS Lett. 2018, 592, 2884–2900. [CrossRef] [PubMed]
12. Saal, S.; Harvey, S.J. MicroRNAs and the kidney: Coming of age. Curr. Opin. Nephrol. Hypertens. 2009, 18,
317–323. [CrossRef] [PubMed]
13. Trionfini, P.; Benigni, A.; Remuzzi, G. MicroRNAs in kidney physiology and disease. Nat. Rev. Nephrol. 2015,
11, 23–33. [CrossRef] [PubMed]
14. Bowen, T.; Jenkins, R.H.; Fraser, D.J. MicroRNAs, transforming growth factor beta-1, and tissue fibrosis.
J. Pathol. 2013, 229, 274–285. [CrossRef] [PubMed]
15. Bhatt, K.; Mi, Q.S.; Dong, Z. MicroRNAs in kidneys: Biogenesis, regulation, and pathophysiological roles.
Am. J. Physiol. Renal Physiol. 2011, 300, F602–F610. [CrossRef] [PubMed]
16. Kato, M.; Arce, L.; Natarajan, R. MicroRNAs and their role in progressive kidney diseases. Clin. J. Am.
Soc. Nephrol. 2009, 4, 1255–1266. [CrossRef] [PubMed]
17. Wei, Q.; Mi, Q.S.; Dong, Z. The regulation and function of microRNAs in kidney diseases. IUBMB Life 2013,
65, 602–614. [CrossRef] [PubMed]
18. Simpson, K.; Wonnacott, A.; Fraser, D.J.; Bowen, T. MicroRNAs in diabetic nephropathy: From biomarkers
to therapy. Curr. Diabetes Rep. 2016, 16, 35. [CrossRef] [PubMed]
19. Wonnacott, A.; Bowen, T.; Fraser, D.J. MicroRNAs as biomarkers in chronic kidney disease. Curr. Opin.
Nephrol. Hypertens. 2017, 26, 460–466. [CrossRef] [PubMed]
20. Beltrami, C.; Simpson, K.; Jesky, M.; Wonnacott, A.; Carrington, C.; Holmans, P.; Newbury, L.; Jenkins, R.;
Ashdown, T.; Dayan, C.; et al. Association of elevated urinary miR-126, miR-155, and miR-29b with diabetic
kidney disease. Am. J. Pathol. 2018, 188, 1982–1992. [CrossRef] [PubMed]
21. Abdelfattah, A.M.; Park, C.; Choi, M.Y. Update on non-canonical microRNAs. Biomol. Concepts 2014, 5,
275–287. [CrossRef] [PubMed]
22. Treiber, T.; Treiber, N.; Meister, G. Regulation of microRNA biogenesis and its crosstalk with other cellular
pathways. Nat. Rev. Mol. Cell Biol. 2018. [CrossRef] [PubMed]
23. Bernstein, E.; Kim, S.Y.; Carmell, M.A.; Murchison, E.P.; Alcorn, H.; Li, M.Z.; Mills, A.A.; Elledge, S.J.;
Anderson, K.V.; Hannon, G.J. Dicer is essential for mouse development. Nat. Genet. 2003, 35, 215–217.
[CrossRef] [PubMed]
Non-coding RNA 2018, 4, 30 10 of 13
24. Shi, S.; Yu, L.; Chiu, C.; Sun, Y.; Chen, J.; Khitrov, G.; Merkenschlager, M.; Holzman, L.B.; Zhang, W.;
Mundel, P.; et al. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J. Am.
Soc. Nephrol. 2008, 19, 2159–2169. [CrossRef] [PubMed]
25. Ho, J.; Ng, K.H.; Rosen, S.; Dostal, A.; Gregory, R.I.; Kreidberg, J.A. Podocyte-specific loss of functional
microRNAs leads to rapid glomerular and tubular injury. J. Am. Soc. Nephrol. 2008, 19, 2069–2075. [CrossRef]
[PubMed]
26. Harvey, S.J.; Jarad, G.; Cunningham, J.; Goldberg, S.; Schermer, B.; Harfe, B.D.; McManus, M.T.; Benzing, T.;
Miner, J.H. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease.
J. Am. Soc. Nephrol. 2008, 19, 2150–2158. [CrossRef] [PubMed]
27. Zhdanova, O.; Srivastava, S.; Di, L.; Li, Z.; Tchelebi, L.; Dworkin, S.; Johnstone, D.B.; Zavadil, J.; Chong, M.M.;
Littman, D.R.; et al. The inducible deletion of Drosha and microRNAs in mature podocytes results in a
collapsing glomerulopathy. Kidney Int. 2011, 80, 719–730. [CrossRef] [PubMed]
28. Wei, Q.; Bhatt, K.; He, H.Z.; Mi, Q.S.; Haase, V.H.; Dong, Z. Targeted deletion of Dicer from proximal
tubules protects against renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 2010, 21, 756–761. [CrossRef]
[PubMed]
29. Johanson, T.M.; Lew, A.M.; Chong, M.M. MicroRNA-independent roles of the RNAse III enzymes Drosha
and Dicer. Open Biol. 2013, 3, 130144. [CrossRef] [PubMed]
30. Burger, K.; Gullerova, M. Swiss army knives: Non-canonical functions of nuclear Drosha and dicer. Nat. Rev.
Mol. Cell Biol. 2015, 16, 417–430. [CrossRef] [PubMed]
31. Rong, L.; Arthur, C.K.C.; Xueqing, Y.; Hui, Y.L. MicroRNAs in diabetic kidney disease. Int. J. Endocrinol.
2014, 2014. [CrossRef]
32. Gomez, I.G.; Nakagawa, N.; Duffield, J.S. MicroRNAs as novel therapeutic targets to treat kidney injury and
fibrosis. Am. J. Physiol. Renal Physiol. 2016, 310, F931–F944. [CrossRef] [PubMed]
33. Kato, M.; Zhang, J.; Wang, M.; Lanting, L.; Yuan, H.; Rossi, J.J.; Natarajan, R. MicroRNA-192 in diabetic
kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors.
Proc. Natl. Acad. Sci. USA 2007, 104, 3432–3437. [CrossRef] [PubMed]
34. Krupa, A.; Jenkins, R.; DongLuo, D.; Lewis, A.; Phillips, A.; Fraser, D. Loss of microRNA-192 promotes
fibrogenesis in diabetic nephropathy. J. Am. Soc. Nephrol. 2010, 21, 438–447. [CrossRef] [PubMed]
35. Wang, B.; Herman-Edelstein, M.; Koh, P.; Burns, W.; Jandeleit-Dahm, K.; Watson, A.; Saleem, M.; Goodall, G.J.;
Twigg, S.M.; Cooper, M.E.; et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that
is independent of the profibrotic effects of transforming growth factor-β. Diabetes 2010, 59, 1794–1802.
[CrossRef] [PubMed]
36. Long, J.; Wang, Y.; Wang, W.; Chang, B.H.; Danesh, F.R. MicroRNA-29c is a signature microRNA under
high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of
diabetic nephropathy. J. Biol. Chem. 2011, 286, 11837–11848. [CrossRef] [PubMed]
37. Mu, J.; Pang, Q.; Guo, Y.H.; Chen, J.G.; Zeng, W.; Huang, Y.J.; Zhang, J.; Feng, B. Functional implications
of microRNA-215 in TGF-β1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1.
PLoS ONE 2013, 8, e58622. [CrossRef] [PubMed]
38. Chung, A.C.; Dong, Y.; Yang, W.; Zhong, X.; Li, R.; Lan, H.Y. Smad7 suppresses renal fibrosis via altering
expression of TGF-β/smad3-regulated microRNAs. Mol. Ther. 2013, 21, 388–398. [CrossRef] [PubMed]
39. Gomez, I.G.; MacKenna, D.A.; Johnson, B.G.; Kaimal, V.; Roach, A.M.; Ren, S.; Nakagawa, N.; Xin, C.;
Newitt, R.; Pandya, S.; et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression
by stimulating metabolic pathways. J. Clin. Investig. 2015, 125, 141–156. [CrossRef] [PubMed]
40. Wang, J.Y.; Gao, Y.B.; Ma, M.F.; Li, M.Z.; Zou, D.W.; Yang, J.K.; Zhu, Z.Y.; Zhao, X. Effect of miR-21 on renal
fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. Cell Biochem. Biophys. 2013,
67, 537–546. [CrossRef] [PubMed]
41. Zhang, Z.; Peng, H.; Chen, J.; Chen, X.; Han, F.; Xu, X.; He, X.; Yan, N. MicroRNA-21 protects from
mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett. 2009, 583, 2009–2014.
[CrossRef] [PubMed]
42. Kato, M.; Arce, L.; Wang, M.; Putta, S.; Lanting, L.; Natarajan, R. A microRNA circuit mediates transforming
growth factor-β1 autoregulation in renal glomerular mesangial cells. Kidney Int. 2011, 80, 358–368. [CrossRef]
[PubMed]
Non-coding RNA 2018, 4, 30 11 of 13
43. Park, J.T.; Kato, M.; Yuan, H.; Castro, N.; Lanting, L.; Wang, M.; Natarajan, R. FOG2 protein down-regulation
by transforming growth factor-β1-induced microRNA-200b/c leads to Akt kinase activation and glomerular
mesangial hypertrophy related to diabetic nephropathy. J. Biol. Chem. 2013, 288, 22469–22480. [CrossRef]
[PubMed]
44. Chen, H.Y.; Zhong, X.; Huang, X.R.; Meng, X.M.; You, Y.; Chung, A.C.; Lan, H.Y. MicroRNA-29b inhibits
diabetic nephropathy in db/db mice. Mol. Ther. 2014, 22, 842–853. [CrossRef] [PubMed]
45. Kato, M.; Wang, L.; Putta, S.; Wang, M.; Yuan, H.; Sun, G.; Lanting, L.; Todorov, I.; Rossi, J.J.; Natarajan, R.
Post-transcriptional up-regulation of tsc-22 by ybx1, a target of miR-216a, mediates TGF-β-induced collagen
expression in kidney cells. J. Biol. Chem. 2010, 285, 34004–34015. [CrossRef] [PubMed]
46. Fu, Y.B.; Zhang, Y.; Wang, Z.Y.; Wang, L.L.; Wei, X.B.; Zhang, B.; Wen, Z.Q.; Fang, H.; Pang, Q.; Yi, F.
Regulation of NADDPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in
experimental diabetic nephropathy. Am. J. Nephrol. 2010, 32, 581–589. [CrossRef] [PubMed]
47. Du, B.; Ma, L.M.; Huang, M.B.; Zhou, H.; Huang, H.L.; Shao, P.; Chen, Y.Q.; Qu, L.H. High glucose
down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett. 2010, 584, 811–816.
[CrossRef] [PubMed]
48. van Niel, G.; D’Angelo, G.; Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev.
Mol. Cell Biol. 2018, 19, 213–228. [CrossRef] [PubMed]
49. Thery, C.; Regnault, A.; Garin, J.; Wolfers, J.; Zitvogel, L.; Ricciardi-Castagnoli, P.; Raposo, G.; Amigorena, S.
Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock
protein Hsc73. J. Cell. Biol. 1999, 147, 599–610. [CrossRef] [PubMed]
50. Blanchard, N.; Lankar, D.; Faure, F.; Regnault, A.; Dumont, C.; Raposo, G.; Hivroz, C. TCR activation of
human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J. Immunol. 2002,
168, 3235–3241. [CrossRef] [PubMed]
51. Raposo, G.; Nijman, H.W.; Stoorvogel, W.; Liejendekker, R.; Harding, C.V.; Melief, C.J.; Geuze, H.J. B
lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996, 183, 1161–1172. [CrossRef] [PubMed]
52. Vrijsen, K.R.; Sluijter, J.P.; Schuchardt, M.W.; van Balkom, B.W.; Noort, W.A.; Chamuleau, S.A.;
Doevendans, P.A. Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial
cells. J. Cell. Mol. Med. 2010, 14, 1064–1070. [CrossRef] [PubMed]
53. Zhan, R.; Leng, X.; Liu, X.; Wang, X.; Gong, J.; Yan, L.; Wang, L.; Wang, Y.; Qian, L.J. Heat shock protein
70 is secreted from endothelial cells by a non-classical pathway involving exosomes. Biochem. Biophys.
Res. Commun. 2009, 387, 229–233. [CrossRef] [PubMed]
54. Raposo, G.; Tenza, D.; Mecheri, S.; Peronet, R.; Bonnerot, C.; Desaymard, C. Accumulation of major
histocompatibility complex class II molecules in mast cell secretory granules and their release upon
degranulation. Mol. Biol. Cell. 1997, 8, 2631–2645. [CrossRef] [PubMed]
55. van Niel, G.; Raposo, G.; Candalh, C.; Boussac, M.; Hershberg, R.; Cerf-Bensussan, N.; Heyman, M. Intestinal
epithelial cells secrete exosome-like vesicles. Gastroenterology 2001, 121, 337–349. [CrossRef] [PubMed]
56. Mears, R.; Craven, R.A.; Hanrahan, S.; Totty, N.; Upton, C.; Young, S.L.; Patel, P.; Selby, P.J.; Banks, R.E.
Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis
and mass spectrometry. Proteomics 2004, 4, 4019–4031. [CrossRef] [PubMed]
57. Ogawa, Y.; Miura, Y.; Harazono, A.; Kanai-Azuma, M.; Akimoto, Y.; Kawakami, H.; Yamaguchi, T.;
Toda, T.; Endo, T.; Tsubuki, M.; et al. Proteomic analysis of two types of exosomes in human whole
saliva. Biol. Pharm. Bull. 2011, 34, 13–23. [CrossRef] [PubMed]
58. Caby, M.P.; Lankar, D.; Vincendeau-Scherrer, C.; Raposo, G.; Bonnerot, C. Exosomal-like vesicles are present
in human blood plasma. Int. Immunol. 2005, 17, 879–887. [CrossRef] [PubMed]
59. Street, J.M.; Barran, P.E.; Mackay, C.L.; Weidt, S.; Balmforth, C.; Walsh, T.S.; Chalmers, R.T.; Webb, D.J.;
Dear, J.W. Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J. Transl. Med.
2012, 10, 5. [CrossRef] [PubMed]
60. Keller, S.; Rupp, C.; Stoeck, A.; Runz, S.; Fogel, M.; Lugert, S.; Hager, H.D.; Abdel-Bakky, M.S.; Gutwein, P.;
Altevogt, P. CD24 is a marker of exosomes secreted into urine and amniotic fluid. Kidney Int. 2007, 72,
1095–1102. [CrossRef] [PubMed]
61. Bard, M.P.; Hegmans, J.P.; Hemmes, A.; Luider, T.M.; Willemsen, R.; Severijnen, L.A.; van Meerbeeck, J.P.;
Burgers, S.A.; Hoogsteden, H.C.; Lambrecht, B.N. Proteomic analysis of exosomes isolated from human
malignant pleural effusions. Am. J. Respir. Cell Mol. Biol. 2004, 31, 114–121. [CrossRef] [PubMed]
Non-coding RNA 2018, 4, 30 12 of 13
62. Pisitkun, T.; Shen, R.F.; Knepper, M.A. Identification and proteomic profiling of exosomes in human urine.
Proc. Natl. Acad. Sci. USA 2004, 101, 13368–13373. [CrossRef] [PubMed]
63. Valadi, H.; Ekstrom, K.; Bossios, A.; Sjostrand, M.; Lee, J.J.; Lotvall, J.O. Exosome-mediated transfer of
mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell. Biol. 2007, 9,
654–659. [CrossRef] [PubMed]
64. Knepper, M.; Pisitkun, T. Exosomes in urine: Who would have thought . . . ? Kidney Int. 2007, 72, 1043–1045.
[CrossRef] [PubMed]
65. Gonzales, P.A.; Pisitkun, T.; Hoffert, J.D.; Tchapyjnikov, D.; Star, R.A.; Kleta, R.; Wang, N.S.; Knepper, M.A.
Large-scale proteomics and phosphoproteomics of urinary exosomes. J. Am. Soc. Nephrol. 2009, 20, 363–379.
[CrossRef] [PubMed]
66. Sugiyama, R.H.; Blank, A.; Dekker, C.A. Multiple ribonucleases of human urine. Biochemistry 1981, 20,
2268–2274. [CrossRef] [PubMed]
67. Reijns, M.A.; Jackson, A.P. Ribonuclease H2 in health and disease. Biochem. Soc. Trans. 2014, 42, 717–725.
[CrossRef] [PubMed]
68. Lu, L.; Li, J.; Moussaoui, M.; Boix, E. Immune modulation by human secreted RNAses at the extracellular
space. Front. Immunol. 2018, 9, 1012. [CrossRef] [PubMed]
69. Beltrami, C.; Clayton, A.; Newbury, L.J.; Corish, P.; Jenkins, R.H.; Phillips, A.O.; Fraser, D.J.; Bowen, T.
Stabilization of urinary microRNAs by association with exosomes and argonaute 2 protein. Noncoding RNA
2015, 1, 151–166. [CrossRef] [PubMed]
70. Lawrie, C.H.; Gal, S.; Dunlop, H.M.; Pushkaran, B.; Liggins, A.P.; Pulford, K.; Banham, A.H.; Pezzella, F.;
Boultwood, J.; Wainscoat, J.S.; et al. Detection of elevated levels of tumour-associated microRNAs in serum
of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141, 672–675. [CrossRef] [PubMed]
71. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.;
Noteboom, J.; O’Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for
cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513–10518. [CrossRef] [PubMed]
72. Arroyo, J.D.; Chevillet, J.R.; Kroh, E.M.; Ruf, I.K.; Pritchard, C.C.; Gibson, D.F.; Mitchell, P.S.; Bennett, C.F.;
Pogosova-Agadjanyan, E.L.; Stirewalt, D.L.; et al. Argonaute2 complexes carry a population of circulating
microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. USA 2011, 108, 5003–5008.
[CrossRef] [PubMed]
73. Turchinovich, A.; Weiz, L.; Langheinz, A.; Burwinkel, B. Characterization of extracellular circulating
microRNA. Nucleic Acids Res. 2011, 39, 7223–7233. [CrossRef] [PubMed]
74. Sharkey, J.W.; Antoine, D.J.; Park, B.K. Validation of the isolation and quantification of kidney enriched
miRNAs for use as biomarkers. Biomarkers 2012, 17, 231–239. [CrossRef] [PubMed]
75. Turchinovich, A.; Tonevitsky, A.G.; Burwinkel, B. Extracellular miRNA: A collision of two paradigms.
Trends Biochem. Sci. 2016, 41, 883–892. [CrossRef] [PubMed]
76. Sanz-Rubio, D.; Martin-Burriel, I.; Gil, A.; Cubero, P.; Forner, M.; Khalyfa, A.; Marin, J.M. Stability of
circulating exosomal miRNAs in healthy subjects. Sci. Rep. 2018, 8, 10306. [CrossRef] [PubMed]
77. Wang, K.; Zhang, S.; Weber, J.; Baxter, D.; Galas, D.J. Export of microRNAs and microRNA-protective protein
by mammalian cells. Nucleic Acids Res. 2010, 38, 7248–7259. [CrossRef] [PubMed]
78. Turchinovich, A.; Weiz, L.; Burwinkel, B. Extracellular miRNAs: The mystery of their origin and function.
Trends Biochem. Sci. 2012, 37, 460–465. [CrossRef] [PubMed]
79. Liang, H.; Gong, F.; Zhang, S.; Zhang, C.Y.; Zen, K.; Chen, X. The origin, function, and diagnostic potential of
extracellular microRNAs in human body fluids. Wiley Interdiscip. Rev. RNA 2014, 5, 285–300. [CrossRef]
[PubMed]
80. Beltrami, C.; Clayton, A.; Phillips, A.O.; Fraser, D.J.; Bowen, T. Analysis of urinary microRNAs in chronic
kidney disease. Biochem. Soc. Trans. 2012, 40, 875–879. [CrossRef] [PubMed]
81. Khalid, U.; Ablorsu, E.; Szabo, L.; Jenkins, R.H.; Bowen, T.; Chavez, R.; Fraser, D.J. MicroRNA-21 (miR-21)
expression in hypothermic machine perfusate may be predictive of early outcomes in kidney transplantation.
Clin. Transpl. 2016, 30, 99–104. [CrossRef] [PubMed]
82. Lopez-Anton, M.; Lambie, M.; Lopez-Cabrera, M.; Schmitt, C.P.; Ruiz-Carpio, V.; Bartosova, M.; Schaefer, B.;
Davies, S.; Stone, T.; Jenkins, R.; et al. MiR-21 promotes fibrogenesis in peritoneal dialysis. Am. J. Pathol.
2017, 187, 1537–1550. [CrossRef] [PubMed]
Non-coding RNA 2018, 4, 30 13 of 13
83. Thery, C.; Amigorena, S.; Raposo, G.; Clayton, A. Isolation and characterization of exosomes from cell culture
supernatants and biological fluids. Curr. Protoc. Cell Biol. 2006, 30, 3–22. [CrossRef] [PubMed]
84. Vickers, K.C.; Palmisano, B.T.; Shoucri, B.M.; Shamburek, R.D.; Remaley, A.T. MicroRNAs are transported
in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell. Biol. 2011, 13, 423–433.
[CrossRef] [PubMed]
85. Michell, D.L.; Vickers, K.C. Lipoprotein carriers of microRNAs. Biochim. Biophys. Acta 2016, 1861, 2069–2074.
[CrossRef] [PubMed]
86. Allen, R.M.; Zhao, S.; Ramirez Solano, M.A.; Zhu, W.; Michell, D.L.; Wang, Y.; Shyr, Y.; Sethupathy, P.;
Linton, M.F.; Graf, G.A.; et al. Bioinformatic analysis of endogenous and exogenous small RNAs on
lipoproteins. J. Extracell Vesicles 2018, 7, 1506198. [CrossRef] [PubMed]
87. Skog, J.; Wurdinger, T.; van Rijn, S.; Meijer, D.; Gainche, L.; Sena-Esteves, M.; Curry, W.T.; Carter, R.S.;
Krichevsky, A.M.; Breakefield, X.O. Glioblastoma microvesicles transport RNA and protein that promote
tumor growth and provide diagnostic biomarkers. Nat. Cell. Biol. 2008, 10, 1470–1476. [CrossRef] [PubMed]
88. Mateescu, B.; Kowal, E.J.; van Balkom, B.W.; Bartel, S.; Bhattacharyya, S.N.; Buzas, E.I.; Buck, A.H.;
de Candia, P.; Chow, F.W.; Das, S.; et al. Obstacles and opportunities in the functional analysis of extracellular
vesicle RNA—An ISEV position paper. J. Extracell Vesicles 2017, 6, 1286095. [CrossRef] [PubMed]
89. Pegtel, D.M.; Cosmopoulos, K.; Thorley-Lawson, D.A.; van Eijndhoven, M.A.; Hopmans, E.S.;
Lindenberg, J.L.; de Gruijl, T.D.; Wurdinger, T.; Middeldorp, J.M. Functional delivery of viral miRNAs
via exosomes. Proc. Natl. Acad. Sci. USA 2010, 107, 6328–6333. [CrossRef] [PubMed]
90. Guescini, M.; Genedani, S.; Stocchi, V.; Agnati, L.F. Astrocytes and glioblastoma cells release exosomes
carrying mtDNA. J. Neural Transm. (Vienna) 2010, 117, 1–4. [CrossRef] [PubMed]
91. Zernecke, A.; Bidzhekov, K.; Noels, H.; Shagdarsuren, E.; Gan, L.; Denecke, B.; Hristov, M.;
Koppel, T.; Jahantigh, M.N.; Lutgens, E.; et al. Delivery of microRNA-126 by apoptotic bodies induces
CXCL12-dependent vascular protection. Sci. Signal. 2009, 2, ra81. [CrossRef] [PubMed]
92. Collino, F.; Deregibus, M.C.; Bruno, S.; Sterpone, L.; Aghemo, G.; Viltono, L.; Tetta, C.; Camussi, G.
Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle
selected pattern of miRNAs. PLoS ONE 2010, 5, e11803. [CrossRef] [PubMed]
93. Zhang, Y.; Liu, D.; Chen, X.; Li, J.; Li, L.; Bian, Z.; Sun, F.; Lu, J.; Yin, Y.; Cai, X.; et al. Secreted monocytic
miR-150 enhances targeted endothelial cell migration. Mol. Cell 2010, 39, 133–144. [CrossRef] [PubMed]
94. Hergenreider, E.; Heydt, S.; Treguer, K.; Boettger, T.; Horrevoets, A.J.; Zeiher, A.M.; Scheffer, M.P.;
Frangakis, A.S.; Yin, X.; Mayr, M.; et al. Atheroprotective communication between endothelial cells and
smooth muscle cells through miRNAs. Nat. Cell. Biol. 2012, 14, 249–256. [CrossRef] [PubMed]
95. Pan, S.; Yang, X.; Jia, Y.; Li, R.; Zhao, R. Microvesicle-shuttled miR-130b reduces fat deposition in recipient
primary cultured porcine adipocytes by inhibiting PPAR-g expression. J. Cell. Physiol. 2014, 229, 631–639.
[CrossRef] [PubMed]
96. Gildea, J.J.; Seaton, J.E.; Victor, K.G.; Reyes, C.M.; Wang, D.B.; Pettigrew, A.C.; Courtner, C.E.; Shah, N.;
Tran, H.T.; Van Sciver, R.E.; et al. Exosomal transfer from human renal proximal tubule cells to distal tubule
and collecting duct cells. Clin. Biochem. 2014, 47, 89–94. [CrossRef] [PubMed]
97. Gracia, T.; Wang, X.N.; Su, Y.; Norgett, E.E.; Williams, T.L.; Moreno, P.; Micklem, G.; Frankl, F.E.K. Urinary
exosomes contain microRNAs capable of paracrine modulation of tubular transporters in kidney. Sci. Rep.
2017, 7, 40601. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
